A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.
Non-Hodgkin's Lymphoma
DRUG: PRO95780|DRUG: rituximab
Objective response, as determined by independent review facility, 8 months
Progression-free survival, as determined by independent review facility, up to 12 months|Duration of objective response, as determined by independent review facility, up to 10.3 months|Overall survival, Up to 18.5 months|Objective response, as determined by the investigator, Up to 8 months|Progression-free survival, as determined by the investigator, Up to 18.5 months|Duration of objective response, as determined by the investigator, Up to 14.1 months
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.